Tirzepatide tends to cause more overall weight loss than semaglutide
However, there is no evidence that the medication's efficacy for weight loss or glycemic control is diminished in patients without gallbladders
After stopping treatment, studies have shown that most patients put the weight back on shortly afterindividuals who continued to use the drug lost 8% of their body weight
This assessment focused on various factors including randomized sequence generation, treatment allocation concealment, blinding, completeness of outcome data, as well as selective outcome reporting and other potential sources of bias
Optum recently reviewed more than 450 research sources addressing AI in healthcare. What we found was eye-opening: AI in healthcare is moving from conception to operational reality across claims, eligibility, service, revenue cycle, care delivery and research
Results Data were collected between January 1, 2020, and June 30, 2020